Significant adjustments to the sales team of well-known pharmaceutical companies

Today (December 1, 2020), the Cardiovascular Division and the Basic Diseases Division will be merged into the new Cardiovascular, Kidney and Metabolism Unit (CRM BU), Novarce has released a full email.
at the same time, we have integrated the transplant and respiratory teams in the field, established the transplant and respiratory diseases team, and established the Transplant and Respiratory BU.
Novarma said in an email that the merger of the new Cardiovascular, Kidney and Metabolic Divisions is one of the strategic initiatives taken by the company to integrate resources, promote innovation, strengthen the grass roots and contribute to Novarma Pharmaceuticals' sustainable development in China, and the newly established division will also be directly connected to the CRM division, the headquarters of one of Novarce Pharmaceuticals' five global business units.
Will be the head of the Cardiovascular, Kidney and Metabolic Division.
Executive Director Lu Zhong, Senior Regional Director Su Wei, Regional Director Xue Tianwen, Zhao Bo, Zhang Jinchao, Dai Chang, County Regional Director Guo Jiangfeng, and Core Marketing Director Prince Wen, Broad Market and Innovation Senior Marketing Director Zhang Wei, will report directly to Yan Qiong.
and the establishment of the Transplant and Respiratory Division will enhance synergies across disease areas and help Novartic's innovative drugs in the field of transplantation and respiratory medicine enter China more quickly and benefit patients.
Wang Jia will be the head of the transplant and respiratory division.
, head of the field of transplant diseases, and Liu Li, head of the field of respiratory diseases, will report directly to Wang Jia.
, head of Novart's Hong Kong operations, will also report directly to Wang Jia.
confirmed the authenticity of the information from authoritative sources.
sector with the largest increase in the number of enterprises, ushered in the restructuring in fact, Novar3 this time the structure adjustment was born in March this year, the establishment of the basic diseases division.
March 25, Novarma Pharmaceuticals China President Zhang Ying announced an organizational restructuring to employees and the establishment of a new Basic Diseases Division.
this division is integrated between the metabolic team of the Metabolism and Transplantation Division and the Hypertension and Hyperlipidemia Division.
, the transplant team of the Metabolism and Transplant Division was established as an independent Transplant Division, focusing on business development in the transplant sector and subsequent new product launches.
county teams in the High Blood Pressure and Hyperlipidemia division were transferred to the Cardiovascular Division and the community team to the Business and Emerging Markets business unit.
that is, the Cardiovascular Division and the Basic Diseases Division, which are officially merged today, include the past metabolic teams, the Hypertension and Hyperlipidemia Division, and the county-level teams of the Hypertension and Hyperlipidemia Division.
and today's new Transplant and Respiratory Division includes the original transplant and respiratory teams.
According to Novarma's previously reported 2020 half-year results, first-half revenue was $23.631 billion, of which the innovative pharmaceutical sector revenue was $18.94 billion, or 5 percent, or 80 percent, and Sanders ( generics) revenue was $4.69 billion, or 20 percent.
Despite the impact and impact of the outbreak, the overall performance of the innovative pharmaceutical business is good, in addition to the ophthalmology business (-9%), the other five sub-businesses have achieved positive growth, including cardiovascular, kidney and metabolic, neurological diseases, immunity, liver and skin, tumors, respiratory diseases increased by 46%, 22%, 16%, 4%, 1%, respectively.
, kidney and metabolic business growth was most pronounced, driven mainly by the strength of the heart failure drug Entersto.
data show that in the Chinese market, Entresto (Nohinto, Chinese Universal Name: Shakuba Qusatan sodium tablets) was approved on July 26, 2017 for adult chronic heart failure patients with reduced blood test scores to reduce their risk of cardiovascular death and hospitalization for heart failure.
2018, global sales of the product reached $1,028 million, up 103 percent from 2017, and have since entered the ranks of heavy bomb drugs.
's semi-annual report shows a significant 46 percent increase in cardiovascular, kidney and metabolic business, which could be adjusted or further optimized for future drug promotion plans thanks to Entersto.
is understood to have grown 19 per cent in the first half of 2020, with revenue of $1.25bn, or 5 per cent of total revenue, driven mainly by new drugs Endresto and Cosentyx.
, which grew 172 percent and 38 percent year-on-year in the first and second quarters, has become the new standard treatment for patients with chronic heart failure, with first-half revenue up to $1.15 billion, according to Southwest Securities Research.
the integration of Novaral's cardiovascular division this time mean that the future sales team of the bombshell will also make adjustments? This deserves follow-up attention.
A number of sales positions, will change for pharmaceutical representatives, the company's business division adjustment and merger, is a certain degree of change, changes will face the adjustment of the team, a group of people get promoted, a group of people are helpless out.
, according to Drug Sla, the compensation policy is still good - the combined compensation policy is N3.
but this compensation policy is different, will include a lot of unrealted, such as year-end bonuses, annual leave conversion, MVP bonuses and so on.
For example, AstraZeneca's plan to merge its cardiovascular and diabetes metabolic businesses to form the industry's largest cardiovascular and diabetes unit underscores the company's ambitions in this area and its plans to add jobs and expand its sales team next.
on the other hand, as long as there is a change, there will be a number of management positions out, a large number of employees in the original position will be developed, there will be more medical representatives in the future to get promotion opportunities, or enter Novarma.
。